One of the most serious side effects associated with the therapy of HIV-1 infection is the appearance of viral strains that exhibit resistance to protease inhibitors. The main goal of this project is to understand the molecular mechanisms by which specific mutations in the HIV- 1 protease elicit inhibitor resistance and to incorporate that knowledge in the development of new strategies for drug design. A related goal is to understand the effectiveness of inhibitors against protease molecules from different HIV- 1 subtypes. These proteases contain amino acid variations at several locations, including some that have been associated with drug resistance. The main questions that this project will answer are: 1) How do specific mutations in the protease molecule preferentially lower the binding affinity of inhibitors relative to the substrate? What are the thermodynamic and structural basis of resistance? 2) How effective are current inhibitors against proteases from different HIV- 1 subtypes? While subtype B is the predominant in the United States and has been the target for drug design, other subtypes are prevalent in Africa, Asia and some European countries, and account for most of the HIV-l infections worldwide. 3) Is the thermodynamic origin of the forces that define the binding affinity of inhibitors related to their susceptibility to resistance-causing mutations? Is it possible to identify protease inhibitors with drastically different enthalpy/entropy balances but similar affinities? Do they respond to resistance-causing mutations in a different way? 4) Is it possible to develop molecular design strategies that explicitly consider the susceptibility to resistance causing mutations? These questions will be answered by a combination of experimental thermodynamic measurements (high sensitivity isothermal titration calorimetry and high sensitivity differential scanning calorimetry), structure determination (x-ray crystallography) and structure-based thermodynamic calculations.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM057144-07
Application #
6711093
Study Section
Special Emphasis Panel (ZRG1-AARR-1 (01))
Program Officer
Basavappa, Ravi
Project Start
1998-03-01
Project End
2005-02-28
Budget Start
2004-03-01
Budget End
2005-02-28
Support Year
7
Fiscal Year
2004
Total Cost
$428,423
Indirect Cost
Name
Johns Hopkins University
Department
Biology
Type
Schools of Arts and Sciences
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Chauhan, Jay; Chen, Shen-En; Fenstermacher, Katherine J et al. (2015) Synthetic, structural mimetics of the ?-hairpin flap of HIV-1 protease inhibit enzyme function. Bioorg Med Chem 23:7095-109
Velazquez-Campoy, Adrian; Leavitt, Stephanie A; Freire, Ernesto (2015) Characterization of protein-protein interactions by isothermal titration calorimetry. Methods Mol Biol 1278:183-204
Evans, Sean L; Schön, Arne; Gao, Qimeng et al. (2014) HIV-1 Vif N-terminal motif is required for recruitment of Cul5 to suppress APOBEC3. Retrovirology 11:4
Miura, Takuya; Hidaka, Koushi; Azai, Yukiko et al. (2014) Optimization of plasmepsin inhibitor by focusing on similar structural feature with chloroquine to avoid drug-resistant mechanism of Plasmodium falciparum. Bioorg Med Chem Lett 24:1698-701
Afanador, Gustavo A; Muench, Stephen P; McPhillie, Martin et al. (2013) Discrimination of potent inhibitors of Toxoplasma gondii enoyl-acyl carrier protein reductase by a thermal shift assay. Biochemistry 52:9155-66
Thanigaimalai, Pillaiyar; Konno, Sho; Yamamoto, Takehito et al. (2013) Design, synthesis, and biological evaluation of novel dipeptide-type SARS-CoV 3CL protease inhibitors: structure-activity relationship study. Eur J Med Chem 65:436-47
Liu, Yingyun; Schön, Arne; Freire, Ernesto (2013) Optimization of CD4/gp120 inhibitors by thermodynamic-guided alanine-scanning mutagenesis. Chem Biol Drug Des 81:72-8
Thanigaimalai, Pillaiyar; Konno, Sho; Yamamoto, Takehito et al. (2013) Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: design, synthesis, biological evaluation, and docking studies. Eur J Med Chem 68:372-84
Resendiz, Marino J E; Schon, Arne; Freire, Ernesto et al. (2012) Photochemical control of RNA structure by disrupting ýý-stacking. J Am Chem Soc 134:12478-81
Schon, Arne; Lam, Sonia Y; Freire, Ernesto (2011) Thermodynamics-based drug design: strategies for inhibiting protein-protein interactions. Future Med Chem 3:1129-37

Showing the most recent 10 out of 29 publications